COMMUNIQUÉS West-GlobeNewswire

Actimed Therapeutics Reacquires Global Rights to S-oxprenolol, Broadening Pipeline Opportunity
06/08/2026
London, UK – 6 th August 2026. Actimed Therapeutics Ltd (“Actimed”), a UK based clinical stage specialty pharmaceutical company focused on bringing innovation to the treatment of cancer cachexia and other muscle wasting [...]
IBA Notice of Half Year 2026 Results and Conference Call
06/08/2026
HY26 results webcast to take place on Thursday, 27 August 2026 at 3 p.m. CEST Louvain-la-Neuve, Belgium, 6 August 2026, 7 a.m. - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator [...]
IBA : Publication des résultats du premier semestre 2026 et conférence web
06/08/2026
La conférence sur les résultats du premier semestre 2026 aura lieu le jeudi 27 août 2026 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 06 août 2026, 7h00 - IBA (Ion Beam Applications S.A le leader mondial [...]
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update
06/08/2026
Vivoryon Therapeutics N.V. Reports H1 2026 Financial Results and Provides Business Update Strategic partnering remains a key priority, with multiple strategic discussions progressing, including advanced term sheet [...]
Braveheart Bio Announces Pricing of Upsized Initial Public Offering
06/08/2026
SAN FRANCISCO, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Braveheart Bio, Inc. (Nasdaq: BRVE), a clinical-stage biopharmaceutical company developing next-generation therapeutics for hypertrophic cardiomyopathy (HCM) and other [...]
ARCPOINT ANNOUNCES FAILURE-TO-FILE CEASE TRADE ORDER
06/08/2026
GREENVILLE, South Carolina, Aug. 05, 2026 (GLOBE NEWSWIRE) -- ARCpoint Inc. (TSXV: ARC) (the “ Company ” or “ ARCpoint ”) announces that the British Columbia Securities Commission (the “ BCSC ”), as the Company’s [...]
Leads Biolabs’ Opamtistomig (PD-L1/4-1BB Bispecific Antibody) Advances to Expansion Phase in First-Line Hepatocellular Carcinoma Following Positive Efficacy Signals
06/08/2026
NANJING, China, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that its Phase II clinical study evaluating Opamtistomig (LBL-024 [...]
Tarsus to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026
06/08/2026
IRVINE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that it will host a live webcast at 5:00 a.m. PT / 8:00 a.m. ET on Thursday, August 6, 2026 to report its [...]
CellFiber and Tidewave Bio Enter Collaboration to Evaluate Scalable 3D Manufacturing for Next-Generation Solid Tumor Immunotherapy
06/08/2026
Partnership pairs CellFiber’s proprietary hollow-fiber encapsulation platform with Tidewave Bio’s universal, off-the-shelf cell immunotherapy program in a proof-of-concept process evaluation TOKYO and LOS ANGELES, Aug. [...]
UPDATE - LifeMD Reports Second Quarter 2026 Results
06/08/2026
UPDATE this press release has been updated to remove a duplicate table. Second quarter 2026 revenue of $47.3 million, within the Company’s guidance range of $47 million to $50 million; adjusted EBITDA loss of [...]
Pacific Health Care Organization, Inc. Reports its Second Quarter 2026 Financial Results
05/08/2026
Irvine, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed yesterday with the Securities and Exchange Commission (the “SEC”) its quarterly report on [...]
BioAge Labs Reports Second Quarter 2026 Financial Results and Provides Business Updates
05/08/2026
First participant dosed in QUELL-CV, a Phase 2 dose-ranging proof-of-concept trial of BGE-102 measuring inflammatory and cardiometabolic biomarkers; topline data anticipated in the second half of 2026 QUELL-DME, Phase [...]
Monthly information on share capital and company voting rights
05/08/2026
(Article 223-16 of General Regulation of the French financial markets authority) PARIS, Aug. 05, 2026 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 Date Total number of shares in the [...]
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
05/08/2026
(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers) PARIS, 05 août 2026 (GLOBE NEWSWIRE) -- Place de cotation : Euronext Growth ISIN code: FR0010425595 Date Nombre total d’actions composant le [...]
STERIS Announces Financial Results for Fiscal 2027 First Quarter
05/08/2026
Fiscal 2027 first quarter revenue increased 7%; constant currency organic revenue growth was 6% Fiscal 2027 first quarter as reported diluted EPS increased to $2.04; adjusted EPS per diluted share increased to $2.59 [...]
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update
05/08/2026
– LOQTORZI ® net revenue of $13.6 million in Q2 2026, up 15% over Q1 – – Clinical data continue to mature across programs with emerging evidence of activity with tagmokitug in head and neck cancer – – Projected October [...]
Biofrontera Inc. to Report Second Quarter 2026 Financial Results on August 13, 2026
05/08/2026
WOBURN, Mass., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Biofrontera Inc. (NASDAQ: BFRI) ("Biofrontera" or the "Company"), a U.S. specialty dermatology company commercializing Ameluz ® (aminolevulinic acid hydrochloride) Gel, [...]
Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
05/08/2026
Prioritization of CTIM-76 and CT-202 clinical programs, with initial clinical readouts expected beginning in Q2 2027 Cash and cash equivalents of $43.0 million as of June 30, 2026 expected to fund operations into Q4 [...]
Pennant Reports Second Quarter 2026 Results
05/08/2026
Conference Call and Webcast scheduled for tomorrow, August 6, 2026 at 10:00 am MT EAGLE, Idaho, Aug. 05, 2026 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of the Pennant group of [...]

Pages